DE60129322D1 - Apoptotische körper zur verwendung in der behandlung von neurodegenerativen und sonstigen nervenerkrankungen - Google Patents

Apoptotische körper zur verwendung in der behandlung von neurodegenerativen und sonstigen nervenerkrankungen

Info

Publication number
DE60129322D1
DE60129322D1 DE60129322T DE60129322T DE60129322D1 DE 60129322 D1 DE60129322 D1 DE 60129322D1 DE 60129322 T DE60129322 T DE 60129322T DE 60129322 T DE60129322 T DE 60129322T DE 60129322 D1 DE60129322 D1 DE 60129322D1
Authority
DE
Germany
Prior art keywords
treatment
apoptotic bodies
patient
nerve diseases
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60129322T
Other languages
English (en)
Other versions
DE60129322T2 (de
Inventor
Daniel Sauder
Arkady Mandel
Anthony E Bolton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasogen Ireland Ltd
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Application granted granted Critical
Publication of DE60129322D1 publication Critical patent/DE60129322D1/de
Publication of DE60129322T2 publication Critical patent/DE60129322T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46432—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE2001629322 2000-05-25 2001-05-25 Apoptotische körper zur verwendung in der behandlung von neurodegenerativen und sonstigen nervenerkrankungen Expired - Fee Related DE60129322T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2309424 2000-05-25
CA 2309424 CA2309424A1 (en) 2000-05-25 2000-05-25 Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
PCT/CA2001/000759 WO2001089537A2 (en) 2000-05-25 2001-05-25 Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders

Publications (2)

Publication Number Publication Date
DE60129322D1 true DE60129322D1 (de) 2007-08-23
DE60129322T2 DE60129322T2 (de) 2008-03-13

Family

ID=4166243

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2001629322 Expired - Fee Related DE60129322T2 (de) 2000-05-25 2001-05-25 Apoptotische körper zur verwendung in der behandlung von neurodegenerativen und sonstigen nervenerkrankungen

Country Status (13)

Country Link
US (3) US7132285B2 (de)
EP (1) EP1289535B1 (de)
JP (1) JP2003534282A (de)
AT (1) ATE366581T1 (de)
AU (1) AU2001261987A1 (de)
CA (1) CA2309424A1 (de)
DE (1) DE60129322T2 (de)
DK (1) DK1289535T3 (de)
ES (1) ES2290134T3 (de)
HK (1) HK1055080A1 (de)
PT (1) PT1289535E (de)
TW (1) TWI239843B (de)
WO (1) WO2001089537A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309518A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
TWI281407B (en) * 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
CA2333494A1 (en) * 2001-02-01 2002-08-01 Vasogen Ireland Limited Blood brain barrier modulation
EP1429727A1 (de) * 2001-09-18 2004-06-23 Vasogen Ireland Limited Apoptose-imitierende synthetische körper und deren verwendung in medizinischer behandlung
US20060008517A1 (en) * 2004-07-09 2006-01-12 Lynch Marina A Treatment of age-related memory impairment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
JP6803339B2 (ja) 2015-04-21 2020-12-23 エンリヴェックス セラピューティクス リミテッド 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
CN109069539A (zh) 2016-02-18 2018-12-21 恩立夫克治疗有限责任公司 用于癌症治疗的联合免疫疗法和细胞因子控制疗法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696092B2 (en) * 1992-02-07 2004-02-24 Vasogen Ireland Limited Endothelial lining effects and treatment of vasospastic disorders
ES2280454T3 (es) 1992-02-07 2007-09-16 Vasogen Ireland Limited Metodo para aumentar la concentracion de oxido nitrico en la sangre.
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
DK1146885T3 (da) * 1999-01-12 2003-09-22 Ct De Rech Du Ct Hospitalier D Forbehandling mod celledød
CA2271190A1 (en) * 1999-05-06 2000-11-06 Vasogen Ireland Limited Improved method for treating mammals with modified mammalian blood
WO2001066875A1 (de) 2000-03-07 2001-09-13 E.F.P. Floor Products Fussböden GmbH Mechanische verbindung von paneelen
CA2309417A1 (en) 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
CA2309518A1 (en) 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
US7122208B2 (en) * 2001-04-06 2006-10-17 Vasogen Ireland Limited Compositions containing apoptotic entities
CN1310652C (zh) 2001-11-29 2007-04-18 特拉科斯有限公司 用体外光提取法和/或凋亡细胞对被试者进行预治疗的方法
US7255880B2 (en) * 2003-04-03 2007-08-14 Vasogen Ireland Limited Treatment of endothelin-related disorders

Also Published As

Publication number Publication date
US20080131416A1 (en) 2008-06-05
WO2001089537A3 (en) 2002-08-01
DE60129322T2 (de) 2008-03-13
TWI239843B (en) 2005-09-21
JP2003534282A (ja) 2003-11-18
DK1289535T3 (da) 2007-11-05
US20070087010A1 (en) 2007-04-19
CA2309424A1 (en) 2001-11-25
US20020044924A1 (en) 2002-04-18
ES2290134T3 (es) 2008-02-16
PT1289535E (pt) 2007-10-19
EP1289535A2 (de) 2003-03-12
AU2001261987A1 (en) 2001-12-03
EP1289535B1 (de) 2007-07-11
US7132285B2 (en) 2006-11-07
ATE366581T1 (de) 2007-08-15
HK1055080A1 (en) 2003-12-24
WO2001089537A2 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
TWI306407B (en) Apparatus and method for generating an electrical signal for use in biomedical applications
DE69721006D1 (de) Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen
DE69316660D1 (de) Terfanadin Metaboliten und deren optisch reine Isomere zur Behandlung von allergischen Krankheiten
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
ES2052733T3 (es) Dispositivo electroterapeutico de baja frecuencia.
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
DE60129322D1 (de) Apoptotische körper zur verwendung in der behandlung von neurodegenerativen und sonstigen nervenerkrankungen
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
DE4394931T1 (de) Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
ATE198550T1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
DE60221283D1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
DE60108130D1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
Smeraski Clonazepam treatment of multi-infarct dementia
ATE281157T1 (de) Zusammensetzung enthaltend di- und trinatriumsalze von echinochrome zur behandlung von augenerkrankungen
SU591196A1 (ru) Способ лечени больных с последстви ми сосудистых заболеваний и травматических повреждений головного мозга
ATE324894T1 (de) Beta-d-2', 3' -didehydro-2', 3' -didesoxy-5- fluorocytidin für die verwendung in der behandlung von hiv infektionen
Schaltenbrand Neuralgia and other pain as observed by the neurologist
RU2554504C1 (ru) Способ лечения лекарственной сиалоаденопатии
RU2090143C1 (ru) Способ лечения сирингомиелии
Almeida‐Lopes et al. Use of low level laser therapy in lymphatic drainage for edema
RU94000695A (ru) Средство с противоаллергическим действием
LANGDON NEUROLOGIC PROGRESS AND PROSPECTS. CHAIRMAN'S ADDRESS, DELIVERED BEFORE THE SECTION ON NERVOUS AND MENTAL DISEASES OF THE AMERICAN MEDICAL ASSOCIATION, AT THE FIFTY-FOURTH ANNUAL SESSION, HELD AT NEW ORLEANS, MAY 5-8, 1903.
Bracken restrictive quarantine.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee